Moderna Shares Drop on Concerns of Lower COVID Vaccine Demand
- Moderna shares fell to almost 3-year low amid concerns about lower COVID-19 vaccine demand
- Moderna reiterated full-year guidance but said it's too early to predict exact demand
- Update came after Pfizer cut outlook due to lack of demand for COVID products
- Moderna expects 2023 sales between $6B-$8B, reiterating previous forecast
- Company says it will have better visibility on U.S. demand by end of month
:max_bytes(150000):strip_icc()/GettyImages-1332309523-ccdb7dc495bc41698fa5e0b179d8746a.jpg)